First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study

被引：3

作者：

Mok, Tony ^{[1
]}

Schmid, Peter ^{[2
]}

De Castro, Gilberto, Jr. ^{[3
]}

Syrigos, Kostas ^{[4
]}

Martin, Claudio ^{[5
]}

Yamamoto, Nobuyuki ^{[6
]}

Aren, Osvaldo ^{[7
]}

Arrieta, Oscar ^{[8
]}

Gottfried, Maya ^{[9
]}

Jazieh, Abdul Rahman ^{[10
]}

Ramlau, Rodryg ^{[11
]}

Timcheva, Constanta ^{[12
]}

Trani, Leonardo ^{[13
]}

机构：

[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

[2] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England

[3] Fac Med Usp, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[4] Univ Athens, Athens, Greece

[5] Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina

[6] Wakayama Med Univ, Dept Expt Therapeut Internal Med Resp Med & Med O, Wakayama, Japan

[7] Ciec Ctr Int Estudios Clin, Dept Oncol, Santiago, Chile

[8] Inst Nacl Cancerol Incan, Thorac Oncol Unit, Mexico City, DF, Mexico

[9] Meir Med Ctr, Dept Oncol, Kefar Sava, Israel

[10] King Saud Univ Hlth Sci Natl Guards Hlth Affairs, Dept Oncol, Riyadh, Saudi Arabia

[11] Poznan Univ Med Sci, Dept Oncol, Poznan, Poland

[12] Mhat Womens Hlth, Med Oncol Clin, Sofia, Bulgaria

[13] Astrazeneca, Royston, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

MEDI4736; tremelimumab; durvalumab; Checkpoint blockade;

D O I：

10.1016/j.jtho.2016.11.1515

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.06-022

引用

页码：S1084 / S1084

页数：1

共 50 条

[41] Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC
Peng, Wenpan
Xu, Yong
Feng, Fanchao
Gu, Cheng
Wang, Zhichao
Han, Di
Zhou, Xianmei
He, Hailang
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
[42] Osimertinib With/Without Platinum-Based Chemotherapy as First-Line Treatment in Patients With EGFRm Advanced NSCLC (FLAURA2)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 3 - 4
[43] IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
Nishio, Makoto
Saito, Haruhiro
Goto, Koichi
Watanabe, Satoshi
Sueoka-Aragane, Naoko
Okuma, Yusuke
Kasahara, Kazuo
Chikamori, Kenichi
Nakagawa, Yuki
Kawakami, Tomohisa
CANCER SCIENCE, 2021, 112 (04) : 1534 - 1544
[44] First-line PD-1 Inhibitor plus Chemotherapy versus Platinum-based Chemotherapy for Patients with Advanced Thymic Carcinoma
Liu, M.
Zhao, J.
Liu, Z.
Hou, X.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S127 - S127
[45] A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma
Yamamoto, Shoma
Kato, Minoru
Takeyama, Yuji
Yukimatsu, Nao
Hirayama, Yukiyoshi
Otoshi, Taiyo
Yamasaki, Takeshi
Kuratsukuri, Katsuyuki
Uchida, Junji
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (05) : 194.e7 - 194.e14
[46] Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Therapy for NSCLC
Gadgeel, Shirish
Gandhi, Leena
Borghaei, Hossein
Socinski, Mark A.
Gubens, Matthew A.
Stevenson, James
Sequist, Lecia V.
Yang, James Chih-Hsin
Papadimitrakopoulou, Vassiliki
Bourque, Jennifer
Bachman, Robert D.
Ge, Joy Yang
Im, Ellie
Patnaik, Amita
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S428 - S428
[47] Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.
Hall, Richard Delmar
Gadgeel, Shirish M.
Garon, Edward B.
Bria, Emilio
Reck, Martin
Vida, John
Zhou, Honghong
Raftopoulos, Harry
Gandhi, Leena
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[48] First-line platinum-based chemotherapy in elderly patients with NSCLC: determinants of therapeutic choice and outcome
Pelizzari, G.
Gerratana, L.
Cattaneo, M.
Cortiula, F.
Lisanti, C.
Bartoletti, M.
Giavarra, M.
Buoro, V.
De Carlo, E.
Macerelli, M.
Poletto, E.
Rossetto, C.
Rizzato, S.
Puglisi, F.
Fasola, G.
ANNALS OF ONCOLOGY, 2017, 28
[49] Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
Liu, Xiaoyan
Lang, Yitian
Chai, Qingqing
Lin, Yan
Liao, Yahui
Zhu, Yizhun
FRONTIERS IN PHARMACOLOGY, 2022, 13
[50] Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Lu, Shun
Wang, Jie
Yu, Yan
Yu, Xinmin
Hu, Yanping
Ai, Xinghao
Ma, Zhiyong
Li, Xingya
Zhuang, Wu
Liu, Yunpeng
Li, Weidong
Cui, Jiuwei
Wang, Dong
Liao, Wangjun
Zhou, Jianying
Wang, Zhehai
Sun, Yuping
Qiu, Xiusong
Gao, Jie
Bao, Yuanyuan
Liang, Liang
Wang, Mengzhao
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1512 - 1522

← 1 2 3 4 5 →